Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 57237-085

8 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 57237-085). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose. The chart compares Rizatriptan Benzoate Tablets at 5 mg and 10 mg strengths with placebo, depicting time post-dose on the x-axis and estimated probability of response on the y-axis.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or placebo for migraine treatment over 24 hours after the initial dose. The vertical axis represents estimated probability of medication rescue, and the horizontal axis shows hours post-dose from 0 to 24.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours after dosing with Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg strengths compared to placebo. The x-axis represents hours post-dose from 0 to 2, and the y-axis shows the estimated probability of response from 0% to 100%. The graph depicts higher response probabilities for both Rizatriptan Benzoate strengths versus placebo over 2 hours.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose or other medication for migraines within 24 hours after an initial dose of Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg compared to placebo. The x-axis represents hours post-dose (0 to 24), and the y-axis represents the estimated probability of remediation or rescue (0% to 100%).*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph titled 'Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7' comparing Rizatriptan Benzoate orally disintegrating tablets with placebo. The x-axis represents hours post stage 2 dose (0.5 to 2.0 hours) and the y-axis shows the percent of patients (0% to 100%) reporting no headache pain, with Rizatriptan showing higher percentages than placebo over time.*
FDA Label Image

Package Label-principal Display Panel (5 mg Unit-Dose Pack (18 Tablets))

Package Label-principal Display Panel (5 mg Unit-Dose Pack (18 Tablets))
Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets USP, 5 mg strength. The label indicates 18 tablets in total, packaged as 3 blister cards of 6 tablets each. It includes the Rising Pharma logo, NDC 57237-085-63, and mentions distribution by Rising Health, LLC. The label also notes phenylalanine content for phenylketonurics and states the tablets are made in India.*
FDA Label Image

Package Label-principal Display Panel (10 mg Unit-Dose Pack (18 Tablets))

Package Label-principal Display Panel (10 mg Unit-Dose Pack (18 Tablets))
Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets USP 10 mg by Rising Pharma Holdings, Inc. The label states the package contains 18 tablets, arranged as 3 blister cards of 6 tablets each. It includes regulatory information, NDC number 57237-086-63, and details that the product is for prescription use only. The label also mentions distribution by Rising Health, LLC and manufacturing in India.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of Rizatriptan Benzoate, showing the molecular arrangement including a triazole ring, indole moiety, and a benzoic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.